Pharmacokinetic Evaluation of Intranasal Nalmefene

* Male or female aged 18 to 55 years inclusive

* BMI ranging from 18 to 30 kg/m2, inclusive

* Adequate venous access

* Subjects must be non-smokers

* History of clinically significant disease

* Significant trauma injury, major surgery, open biopsy within 30 days prior to screening

* Following an abnormal diet 4 weeks prior to screening

* Use of over the counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention

* Use of enzyme altering drugs 30 days before intervention

* Use of nasal products 28 days before intervention and throughout the study

* Previous or current opioid, alcohol, or other drug dependence

* Donated or received blood 30 days before intervention

* Women who are pregnant or breastfeeding at screening

* Women of childbearing potential unless surgically sterile or use effective contraception

* Current or recent upper respiratory tract infection

* Allergic to nalmefene